PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER

QR Code

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER

Based on a clinical study BCIRG 001 (Martin M., Mackey J., Pienkowski T.) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing t...

Full description

Saved in:

Bibliographic Details
Main Authors:	R. I. Yagudina, I. Yu. Zinchuk
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	pharmacoeconomic analysis breast cancer chemotherapy budget impact analysis
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/79
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity
by: A. R. Kasimova, et al.
Published: (2022-11-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014-07-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: A. U. Kulikov, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION
by: R. I. Yagudina, et al.
Published: (2015-03-01)

The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung
by: S. K. Yarovoy, et al.
Published: (2020-04-01)

Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy
by: I. N. Dyakov, et al.
Published: (2021-02-01)

Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01)

MECHANISMS OF ACTIVATION OF HEMATOPOIETIC RECOVERY DUE TO FILGASTRIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN/DOCETAXEL
by: Т. Yu. Khrichkova, et al.
Published: (2016-02-01)

COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer
by: N. S. Besova
Published: (2014-07-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
by: A. V. Rudakova, et al.
Published: (2021-07-01)

The role of Taxotere in adjuvant therapy for early breast cancer
by: I. V. Kolyadina, et al.
Published: (2014-07-01)

Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer
by: S. К. Zyryanov, et al.
Published: (2024-05-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS
by: M. V. Protsenko
Published: (2015-03-01)

Pharmacoeconomics of spastic cerebral palsy
by: R. I. Yagudina, et al.
Published: (2018-02-01)

PHARMACOECONOMIC ANALYSIS OF MARKET OF BIOLOGICALLY ACTIVE ADDITIVES MERCHANDIZED IN PHARMACY ORGANIZATIONS
by: O. V. Belousova, et al.
Published: (2015-12-01)

Comparative pharmacoeconomic analysis of posaconazole therapy in tablet form and in suspension for invasive fungal infections prevention
by: I. S. Krysanov, et al.
Published: (2021-06-01)

Metformin as an adjuvant option for systemic treatment of breast cancer
by: D.I. Avierin, et al.
Published: (2023-12-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE
by: E. I. Tarlovskaya, et al.
Published: (2015-09-01)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-07-01)

Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)
by: D. N. Kravchenko, et al.
Published: (2018-10-01)